Sir,

Embolization therapy with the cyanoacrylate glues; iso-butyl-2-cyanoacrylate (IBCA) and more recently *n*-butyl-2-cyanoacrylate (NBCA) has been performed for 2 decades.\[[@ref1][@ref2]\] Various complications resulting from this therapy have been described, usually related to the central nervous system.\[[@ref3][@ref4]\] Occurrence of seizure during embolization has not been reported yet. Here we have reported a case of seizure as a rare complication during glue embolization of arteriovenous malformation (AVM).

A 35-year-old woman weighing 59 kg, presented with complaints of headache and increasing frequency of left focal seizure with secondary generalization. She had been taking sodium valproate and clobazam for her seizure control. Clinical examination was unremarkable. Cerebral angiography revealed Spetzler grade II right frontal AVM supplied by callosomarginal branch of right anterior cerebral artery (ACA) and draining into superficial venous system. The patient was scheduled for elective embolization of the right frontal AVM. On the day of embolization, along with the prescribed antiepileptics, she was administered loading dose of phenytoin (15 mg/kg). Routine monitors were attached and monitored anesthesia care was provided. Right radial artery was cannulated under local anesthesia for continuous blood pressure monitoring. For conscious sedation, dexmedetomedine was administered as loading dose of 1 μg/kg over 10 min followed by continuous infusion at the rate of 0.5 μg/kg/h. During embolization, initial angiographic run revealed right frontal AVM with nidus measuring 2.4 × 2 cm with feeders from callosomarginal branch of right ACA. Flow-guided microcatheter was negotiated into the nidus through a feeding vessel. After administering hydrocortisone 100 mg intravenous as prophylaxis for anaphylaxis, 0.4 mL of 50% NBCA glue was injected into the nidus and partial obliteration was achieved as revealed by subsequent angiography. Approximately 5 min after glue injection, the patient developed focal seizure of left hand, which became generalized over a period of 20 s. Midazolam 4 mg intravenous was given immediately to abort the seizure. General anesthesia was induced with fentanyl 100 μg, propofol 125 mg; and tracheal intubation was facilitated with rocuronium 60 mg. Anesthesia was maintained with propofol infusion and oxygen in air mixture. She remained hemodynamicaly stable thereafter. Arterial blood gases were within normal limits (pH 7.33, PaO~2~ 380 mmHg, PaCO~2~ 40.9 mmHg, bicarbonate 21.8, and base deficit 4.3). Blood sample for measuring plasma level of antiepileptic agents was dispatched and an additional dose of phenytoin was administered. Check angiography showed partial obliteration of AVM with the large venous pouch still filling. Non-contrast computed tomography (NCCT) head did not reveal any hemorrhage. The procedure was abandoned and the patient was shifted intubated to the intensive care unit (ICU). The plasma level of valproate was found to be within the therapeutic range. Continuous electroencephalography monitoring in the ICU for the next 48 h did not reveal any seizure activity. Tracheal extubation was performed after 18 h of elective ventilation. Repeat NCCT head after 24 h was normal (no evidence of hemorrhage or infarction). The patient was discharged on the fourth postoperative day without any neurologic deficit.

Cerebral AVMs are presumed to be congenital lesions resulting from abnormal vessel malformation during embryonic development. The usual presenting symptoms are seizures, intracranial hemorrhage, progressive neurologic deficit, intractable headache, and hydrocephalus.\[[@ref5]\] Embolization is often performed as an adjunct to surgery or radiotherapy to reduce the nidus size. Many embolic agents have been used to treat brain AVMs. These include microspheres of various types, silk thread, polyvinyl alcohol, avitene, and the liquid cyanoacrylates, including IBCA and NBCA.\[[@ref1][@ref2]\] There are no published reports on the occurrence of seizure during embolization. This patient had a seizure despite adequate plasma concentration of valproate and having received loading dose of phenytoin before the intervention. The probable cause of seizure in this patient was an intense local inflammatory reaction to the glue (NBCA) resulting in abnormal neuronal excitation. IBCA is known to cause an intense inflammatory response in the brain.\[[@ref6]\] These inflammatory changes include perivascular inflammation and vessel wall necrosis as described by Vinters *et al*.,\[[@ref6]\] in their series of 17 surgically resected brain AVMs. An acute polymorphonuclear infiltrate was seen in the first 48 h, with an intense foreign body reaction and necrosis of vessel walls noted in the first week. Necrosis of parenchyma adjacent to embolized vessels also was observed, with IBCA actually migrating into adjacent neuroglial cells. The authors theorized that this intense reaction could be attributable to slight heating of the tissues as the IBCA polymerizes or toxin release as IBCA degrades. Even the continuous infusion of the alpha-2 adrenoceptor, dexmedetomidine, which has been demonstrated to possess anticonvulsant property in models of drug-induced epilepsy, could not prevent the occurrence of seizure.\[[@ref7]\]

In conclusion, seizures may occur during glue embolization of AVMs. Through this report, we also highlight the importance of the use of alpha-2 agonist, dexmedetomidine for conscious sedation, which makes it possible to recognize complication early and for the timely treatment of any antecedent complication(s).
